What is Sim&cure?
Sim&cure operates at the forefront of the MedTech industry, specifically targeting the complex domain of brain aneurysm treatment. The company distinguishes itself through a multifactorial approach that prioritizes patient service and surgical efficacy. Its flagship solution, SimSize, serves as a cornerstone of its product portfolio, designed to assist healthcare professionals in optimizing surgical procedures and improving long-term patient outcomes.
Beyond its core software offerings, Sim&cure maintains a strategic focus on collaborative innovation. By forging partnerships with leading medical imaging companies, the firm enhances the diagnostic capabilities available to clinicians. This ecosystem-based strategy not only streamlines the treatment pathway but also assists healthcare systems in managing costs while maintaining high standards of care. The company's commitment to evidence-based therapeutic solutions positions it as a vital partner for hospitals navigating the complexities of neurovascular intervention.
How much funding has Sim&cure raised?
Sim&cure has raised a total of $11.7M across 1 funding round:
Other Financing Round
$11.7M
Other Financing Round (2025): $11.7M with participation from Sofilaro, Elaia Partners, IRDI Capital Investissement, and SWEN Capital Partners
Key Investors in Sim&cure
Sofilaro
A regional expert in capital investment and a subsidiary of Crédit Agricole, focusing on supporting SMEs and mid-sized enterprises through tailored financial solutions.
Elaia Partners
A full-stack investor specializing in backing ambitious tech disruptors from inception to leadership, with a strong track record in scaling innovative startups.
IRDI Capital Investissement
A major investment partner for innovation in the South-West of France, providing equity financing to foster sustainable growth in SMEs and mid-sized businesses.
What's next for Sim&cure?
Looking ahead, the strategic deployment of this capital will likely focus on expanding the reach of the SimSize platform and deepening the company's research and development pipeline. As Sim&cure transitions into a more mature phase of its lifecycle, the focus will shift toward international market penetration and the potential integration of artificial intelligence to further refine diagnostic accuracy.
The company is expected to leverage its recent backing to strengthen its existing partnerships with imaging providers, ensuring that its therapeutic solutions remain at the cutting edge of clinical practice. By maintaining a focus on sustainable growth and operational excellence, Sim&cure is poised to influence the future of neurovascular surgery, providing hospitals with the tools necessary to deliver superior patient care in an increasingly data-driven healthcare environment.
